Clinical trials: Disorder Heart
Coronary Artery Disease
Development and Translation of Generator-Produced PET Tracer for Myocardial Perfusion Imaging-Dosimetry Group
This study is a single center, early phase 1 clinical imaging study designed to assess the dosimetry of 68Ga-Galmydar for PET/CT imaging.
- Trial name
- GALMYDAR (NCT05280782)
- Testing
- Ga-68 Galmydar
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Cardiac Transplant Disorder
Don't Throw Your Heart Away: Medical Student Study 2
Publicly available outcome assessments for transplant programs do not make salient that some programs tend to reject many of the hearts they are offered, whereas other programs accept a broader range of donor offers.
- Trial name
- NCT04176796
- Testing
- Stratified Transplant Survival
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Carnegie Mellon University
Cardiovascular Diseases, Coronary Artery Disease
ISCHEMIA-Chronic Kidney Disease Trial
The purpose of the ISCHEMIA-CKD trial is to determine the best management strategy for patients with stable ischemic heart disease (SIHD), at least moderate inducible ischemia and advanced chronic kidney disease (CKD; estimated…
- Conditions
- Cardiovascular Diseases, Coronary Artery Disease, Heart Diseases, Myocardial Ischemia
- Trial name
- ISCHEMIA-CKD (NCT01985360)
- Testing
- Cardiac Catheterization, Coronary Artery Bypass Graft Surgery, Percutaneous Coronary Intervention
- Where
- United States
- Volunteers
- 777 people
- Sponsor
- NYU Langone Health
Coronary Artery Disease, Acute Coronary Syndrome
Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor
Recently, two new oral P2Y12 antagonists have been approved for clinical use: prasugrel, a third generation thienopyridine, and ticagrelor, a first in class cyclopentyltriazolopyrimidine (CPTP).
- Trial name
- SWAP3 (NCT02016170)
- Testing
- Ticagrelor 180mg, Prasugrel 10mg, Ticagrelor 90mg
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- University of Florida
Chronic Obstructive Pulmonary Disease (COPD)
Safety and Tolerability of QVA149 (Indacaterol/Glycopyrrolate) Compared to Placebo and to Indacaterol in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)
An investigational inhalation product (QVA149) for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD) is being developed.
- Trial name
- NCT00558285
- Testing
- indacaterol/glycopyrrolate, indacaterol, glycopyrrolate
- Where
- 40 sites in Australia, Belgium and 6 more
- Volunteers
- 257 people
- Sponsor
- Novartis
22Q11.2 Deletion Syndrome
Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome (INSPIRE)
To evaluate the safety and tolerability of ZYN002 administered as a transdermal gel formulation, for up to 38 weeks, in participants ages 4 to <18 years, in the treatment of 22q.11.2 Deletion syndrome (22qDS).
- Trial name
- INSPIRE (NCT05149898)
- Testing
- ZYN002
- Where
- 3 sites in United States, Australia
- Volunteers
- 20 people
- Sponsor
- Harmony Biosciences Management, Inc.
Sudden Cardiac Arrest
The Intrepid Clinical Engineering Study
The purpose of this research study is to collect clinical data to validate a software update for 12-lead electrocardiogram monitoring.
- Trial name
- NCT05636332
- Testing
- 12 lead Electrocardiogram
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Heartstream US LLC
Diabetes Mellitus Type 2
Vildagliptin vs Sitagliptin add-on to Insulin - Impact on Glycemic Profile and Correlation of Hypoglycemic Episodes and Heart Function
Vildagliptin and Sitagliptin both belong to the class of DPP-4 inhibitors, but differ in their pharmacokinetic profile as well as in their approved application (Vildagliptin, 2x 50 mg daily, Sitagliptin, 1x 100 mg daily).
- Trial name
- CGM-VISIT (NCT01686932)
- Testing
- Vildagliptin, Sitagliptin
- Where
- 11 sites in Germany
- Volunteers
- 51 people
- Sponsor
- Novartis Pharmaceuticals
Congestive Heart Failure, Cardiomyopathy
Cardiac Hormone Replacement With Brain Natriuretic Peptide (BNP) in Heart Failure
The purpose of this study is to determine the effects of subcutaneous injection of Human BNP (nesiritide), a hormone produced by the heart, on the pumping ability of the heart, kidney function, and hormonal function in persons…
- Trial name
- SubqBNP (NCT00252187)
- Testing
- B-type Natriuretic Peptide (BNP)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Horng Chen
Heart Failure
Torsemide Comparison With Furosemide for Management of Patients With Stable Heart Failure
The study is designed to be a prospective, randomized study is to compare the effectiveness of two standard of care loop diuretics (furosemide versus torsemide) on clinical outcomes among patients currently on a stable dose of…
- Trial name
- TFO (NCT05093621)
- Testing
- Furosemide, Torsemide
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Yale University
Electronic Fetal Monitoring, Fetal Hypoxia
Oxygen for Intrauterine Resuscitation of Category II Fetal Heart Tracings
Maternal oxygen administration for concerning fetal heart rate tracing (FHT) patterns is common practice on Labor and Delivery units in the United States.
- Conditions
- Electronic Fetal Monitoring, Fetal Hypoxia, Fetal-Placental Circulation
- Trial name
- O2C2 (NCT02741284)
- Testing
- Room air, 10L Oxygen by nonrebreather mask
- Where
- United States
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Vitamin D Deficiency, Cardiomyopathies
Can Vitamin D Reduce Heart Muscle Damage After Bypass Surgery?
Background and study aim: Heart diseases are among the most common causes of death worldwide. A large proportion of deaths are caused by heart attacks (myocardial infarction), where blood flow to the heart is reduced resulting in…
- Conditions
- Vitamin D Deficiency, Cardiomyopathies, Apoptosis, Inflammation
- Trial name
- NCT04323852
- Testing
- Vitamin D
- Where
- Iran
- Volunteers
- 70 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Congenital Heart Disease, Disorder of Fetus or Newborn
Preoperative Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass
Randomized controlled trial of the use of glucocorticoids to improve the clinical course of neonates post-cardiopulmonary bypass (CPB).
- Trial name
- NCT00934843
- Testing
- methylprednisolone (IVMP), methylprednisolone (two doses IVMP)
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Medical University of South Carolina
Heart Failure, Tachyarrhythmia
BIO|MASTER.Ilivia Family / Plexa
Post-Market Clinical Follow-up of the new Ilivia ICD Family and the new Plexa right ventricular lead to fulfill requirements by the notified body and to support regulatory approval outside of the CE region
- Trial name
- NCT02774616
- Testing
- Ilivia ICD Family, Plexa ICD lead
- Where
- 25 sites in Australia, Austria and 8 more
- Volunteers
- 292 people
- Sponsor
- Biotronik SE & Co. KG
Duchenne Muscular Dystrophy, Cardiomyopathy
HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)
Male participants with cardiomyopathy secondary to Duchenne muscular dystrophy (DMD) meeting all inclusion and no exclusion criteria will be randomized. All participants will be at least 12 years of age.
- Trial name
- HOPE (NCT02485938)
- Testing
- Allogeneic Cardiosphere-Derived Cells (CAP-1002)
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Capricor Inc.
HIV
Effects of Eplerenone on Cardiovascular Disease in HIV (MIRACLE HIV Study)
HIV-infected individuals treated with antiretroviral medications are living longer, but have an increased risk of heart disease when compared to non-HIV-infected individuals.
- Trial name
- NCT02740179
- Testing
- Eplerenone, Lifestyle Modification
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Coronary Artery Disease (CAD)
Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)
Observe whether the administration of caffeine prior to regadenoson will affect the interpretation of test results in subjects with coronary artery disease (CAD) undergoing SPECT MPI
- Trial name
- NCT00826280
- Testing
- regadenoson, overencapsulated caffeine, technetium
- Where
- 25 sites in United States
- Volunteers
- 347 people
- Sponsor
- Astellas Pharma Inc
Congestive Heart Failure, Metastatic Cancer
Advance Care Planning in the Emergency Department
This is a two-armed, parallel-design, pre-/post-intervention assessment study. The investigators will conduct a randomized controlled trial for ED GOAL on a cohort of 120 older adults with serious illness to collect…
- Conditions
- Congestive Heart Failure, Metastatic Cancer, Chronic Kidney Disease Requiring Chronic Dialysis, Chronic Obstructive Pulmonary Disease
- Trial name
- NCT05209880
- Testing
- ED GOAL
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- Brigham and Women's Hospital
Sarcoidosis
Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis
The purpose of this research study to find out if a drug called OctreoScan or DOTATATE can help doctors diagnose people with cardiac sarcoidosis better. OctreoScan and DOTATATE are both approved by the U.S.
- Trial name
- NCT02546388
- Testing
- Indium-111 Pentreotide, Gallium-68 DOTATATE
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Marcelo F. Di Carli, MD, FACC
Left Ventricular Systolic Dysfunction, Sudden Cardiac Death
Heart Rate Response to Regadenoson and Sudden Cardiac Death
The purpose of this study is to determine whether a blunted heart rate response to regadenoson is an independent predictor of sudden cardiac death.
- Trial name
- NCT01842035
- Testing
- regadenoson
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Alabama at Birmingham
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.